Image
In 1971, we became one of the country’s first community National Cancer Institute-designated cancer research centers. This designation made us part of an elite group of cancer centers exploring new ways of detecting and treating cancer.
Today, Lehigh Valley Topper Cancer Institute remains at the forefront of cancer care through clinical trials that are making care safer and more effective. You have access to hundreds of clinical trials, some of which are only available in a select number of cancer centers.
Pioneering care
You may be among the first people in the country to receive new treatments because of our participation in early phase clinical trials. These trials are only available in select cancer programs such as ours. LVHN’s decades of experience and multidisciplinary approach ensure you are receiving promising, yet effective, new care options.
Leading-edge therapies
We offer clinical trials in all aspects of cancer care, including new surgical techniques and radiation therapy technologies. Find a cancer clinical trial.
Safety
Our team includes research nurses who are in contact with you throughout your clinical trial experience. These specialists offer an added layer of protection against complications and avoidable side effects. Get more cancer clinical trials patient information.
Access to more options
Through clinical trials, the Cancer Institute tests new treatments, which may transform cancer care. Here are a few examples:
- We are one of few cancer centers in Pennsylvania participating in TAPUR (Targeted Agent and Profiling Utilization Registry), which is advancing cancer care through targeted therapies. This innovative treatment includes cancer drugs that disrupt molecules within cancer cells so they stop growing. Find out more about targeted therapy.
- We participated in the region’s only clinical trial for an immunotherapeutic pancreatic cancer vaccine. The randomized trial is evaluating the drug, ELI-002 7P, which “teaches” the immune system to fight pancreatic cancer recurrence by targeting specific genetic mutations that cause cancer cells to grow.
- We also participated in a phase 2 study of a combination melanoma vaccine that’s giving hope to people with stage 3 and stage 4 cancer. The study is examining a combination vaccine against two immunosuppressive signals seen in cancer, especially in melanoma.
Targeted therapy
We are one of few cancer centers in Pennsylvania participating in TAPUR (Targeted Agent and Profiling Utilization Registry), which is advancing cancer care through targeted therapies. This innovative treatment includes cancer drugs that disrupt molecules within cancer cells so they stop growing. Find out more about targeted therapy.